bioAffinity Technologies, Inc. (BIAFW) स्टॉक विश्लेषण

कंपनी का अवलोकन

bioAffinity Technologies, Inc. (BIAFW) is an enterprise focused on developing non-invasive diagnostic laboratory tests designed to detect early-stage lung cancer and other pulmonary diseases through the application of flow cytometry and automated analysis within the United States. The company currently operates through two distinct segments, namely Diagnostic Research and Development, which are central to its operational strategy for advancing medical diagnostics. Although specific sector and industry classifications are not publicly disclosed in the available data, the firm employs a workforce of 57 individuals to support its research and development initiatives. The company's financial scale is characterized by a trailing twelve-month revenue of $6.16 million, while its market capitalization, price-to-book ratio, and other valuation metrics are either not available or indicate a highly specific valuation structure with a price-to-book of 0.24. These financial figures suggest that the company operates with a capital structure where its market value is significantly lower than its book value, a common characteristic in early-stage biotechnology or diagnostic firms where future potential is not yet fully reflected in current market pricing or where significant intangible assets are held.

वित्तीय स्वास्थ्य

The financial performance of bioAffinity Technologies, Inc. over the trailing twelve months reveals a revenue stream of $6.16 million, contrasted sharply against a net income of -$14,909,754 and an EBITDA of -$10,067,672. The substantial gap between the reported revenue and the significant net loss indicates a cost structure where operating expenses, likely driven by research, development, and administrative costs, far exceed current revenue generation capabilities. The company's free cash flow stands at -$4,933,569, which implies that the business is currently burning cash and lacks the immediate financial flexibility to fund operations entirely from internal cash flows without external capital injections. Margin analysis further elucidates the financial pressure points, with a gross margin of 31.4% suggesting that production costs are managed relatively well against sales, yet this is overwhelmed by an operating margin of -196.9% and a profit margin of -242.0%, highlighting severe operational inefficiencies or high overhead costs relative to sales volume. On the balance sheet, the company holds $6.45 million in cash against $1.16 million in debt, resulting in a debt-to-equity ratio of 15.95, which points to a highly leveraged capital structure where equity is minimal compared to the debt burden. Despite the high leverage, the current ratio of 2.60 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting a degree of short-term liquidity stability. However, the return on equity is reported at -301.8% and the return on assets at -75.6%, metrics that reveal that management effectiveness in generating returns on shareholder capital and total assets is currently negative, a typical challenge for companies in the development phase of their lifecycle.

मूल्यांकन आकलन

Valuation metrics for bioAffinity Technologies, Inc. present a mixed picture due to the absence of traditional profitability-based ratios; the trailing P/E ratio and forward P/E are both not available, which precludes a standard analysis of earnings trajectory or the difference between current and future expectations based on price multiples. Similarly, the price-to-sales ratio and EV/EBITDA are not available, meaning that alternative valuation metrics typically used to gauge a company's value relative to its sales or earnings power cannot be calculated or do not exist in the current dataset. The available price-to-book ratio of 0.24 indicates that the market is valuing the company at a fraction of its book value, suggesting a significant discount relative to the net asset value recorded on the balance sheet. Regarding trading ranges, the 52-week high and low are both recorded at $0.40, which mathematically implies that the stock is trading within a static range with no price movement recorded over the past year, effectively sitting at 0% deviation from both the high and low points. The beta value of -0.81 is an anomalous indicator that suggests the stock price moves inversely to the broader market, exhibiting high volatility in the opposite direction of market trends, although such a negative beta is statistically rare and requires careful interpretation regarding the stock's systematic risk profile.

Growth & Income

The growth profile of bioAffinity Technologies, Inc. is characterized by a year-over-year revenue decline of -27.8%, while earnings growth is not available due to the company's lack of profitability. This contraction in revenue suggests that the company is currently facing headwinds in sales volume or pricing, and since earnings are negative, a direct comparison of earnings versus revenue growth rates is not feasible in the traditional sense of expanding margins or top-line expansion. As the company does not pay dividends, evidenced by the absence of a dividend yield and payout ratio data, it follows a strategy of reinvesting any potential earnings or relying on external funding rather than distributing cash to shareholders. Consequently, the overall growth and income profile for bioAffinity Technologies, Inc. is defined by a shrinking revenue base and a complete absence of dividend income, placing the entire burden of future value creation on the successful execution of its diagnostic research and development segments.